Analysts expect Kalvista Pharmaceuticals Inc (NASDAQ:KALV) to post earnings of ($0.47) per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for Kalvista Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.62) and the highest estimate coming in at ($0.37). Kalvista Pharmaceuticals reported earnings of ($0.50) per share during the same quarter last year, which indicates a positive year over year growth rate of 6%. The firm is expected to issue its next quarterly earnings report on Thursday, December 13th.
According to Zacks, analysts expect that Kalvista Pharmaceuticals will report full year earnings of ($2.07) per share for the current financial year, with EPS estimates ranging from ($2.79) to ($1.69). For the next fiscal year, analysts anticipate that the company will report earnings of ($2.74) per share, with EPS estimates ranging from ($3.59) to ($1.88). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that cover Kalvista Pharmaceuticals.
Kalvista Pharmaceuticals (NASDAQ:KALV) last released its quarterly earnings data on Friday, September 14th. The specialty pharmaceutical company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.14). Kalvista Pharmaceuticals had a negative return on equity of 56.24% and a negative net margin of 132.38%. The company had revenue of $3.72 million for the quarter, compared to analyst estimates of $4.11 million.
Several research analysts have issued reports on the company. Cantor Fitzgerald set a $32.00 price objective on Kalvista Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, October 3rd. BidaskClub upgraded Kalvista Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday, November 22nd. Zacks Investment Research upgraded Kalvista Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, November 20th. Stifel Nicolaus assumed coverage on Kalvista Pharmaceuticals in a research note on Monday, October 15th. They set a “buy” rating for the company. Finally, Jefferies Financial Group assumed coverage on Kalvista Pharmaceuticals in a research note on Tuesday, October 30th. They set a “buy” rating and a $30.00 price objective for the company. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. Kalvista Pharmaceuticals presently has an average rating of “Buy” and an average target price of $25.25.
Kalvista Pharmaceuticals stock opened at $22.91 on Friday. Kalvista Pharmaceuticals has a 52-week low of $7.73 and a 52-week high of $25.57. The firm has a market cap of $392.54 million, a price-to-earnings ratio of -14.97 and a beta of 2.94.
In other Kalvista Pharmaceuticals news, Director Albert Cha bought 1,058,824 shares of the stock in a transaction dated Monday, September 10th. The stock was bought at an average cost of $17.00 per share, for a total transaction of $18,000,008.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 49.10% of the company’s stock.
Several large investors have recently made changes to their positions in the company. Vivo Capital LLC increased its stake in shares of Kalvista Pharmaceuticals by 352.6% in the third quarter. Vivo Capital LLC now owns 1,359,149 shares of the specialty pharmaceutical company’s stock valued at $30,051,000 after buying an additional 1,058,824 shares in the last quarter. VHCP Management III LLC bought a new position in Kalvista Pharmaceuticals in the third quarter valued at about $28,410,000. VHCP Management II LLC bought a new position in Kalvista Pharmaceuticals in the third quarter valued at about $16,785,000. Interwest Venture Management Co. boosted its holdings in Kalvista Pharmaceuticals by 17.8% in the third quarter. Interwest Venture Management Co. now owns 388,766 shares of the specialty pharmaceutical company’s stock valued at $8,596,000 after acquiring an additional 58,824 shares during the last quarter. Finally, Vanguard Group Inc. boosted its holdings in Kalvista Pharmaceuticals by 152.4% in the third quarter. Vanguard Group Inc. now owns 296,581 shares of the specialty pharmaceutical company’s stock valued at $6,558,000 after acquiring an additional 179,092 shares during the last quarter. Institutional investors own 73.16% of the company’s stock.
Kalvista Pharmaceuticals Company Profile
KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.
Read More: Correction
Get a free copy of the Zacks research report on Kalvista Pharmaceuticals (KALV)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.